BMS Signs an Agreement with BioMotiv to Develop Therapies for Patients with Serious Disorder
Bristol-Myers (BMS) Reports Results of Opdivo (nivolumab) + Yervoy (ipilimumab) in P-II CheckMate -650 trial for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Shots:
- BMS & BioMotiv to form and fund new facilities, developing therapies for diseases with unmet medical needs and post identification of the candidate BMS has an option to acquire the new facility. Additionally, BMS has an option to invest additional funding in selected projects of mutual interest
- The focus of the collaboration is combining the strength of both the companies and utilizing them in the development of novel therapies with the translation of transformational discoveries into breakthrough therapies
- BioMotiv’s Harrington Project for Discovery & Development program is US and US initiative of $340M used to support the discovery and development of therapeutic breakthroughs
Click here to read full press release/ article | Ref: BusinessWire | Image: Twitter